<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874051</url>
  </required_header>
  <id_info>
    <org_study_id>1099/IRCCS San Camillo</org_study_id>
    <nct_id>NCT04874051</nct_id>
  </id_info>
  <brief_title>Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases</brief_title>
  <acronym>BALANCE</acronym>
  <official_title>Sensor-Based Analysis And rehabiLitation of bAlance in Neurological Diseases: a multiCentric randomizEd Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Camillo, Venezia, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>I.R.C.C.S. Fondazione Santa Lucia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Camillo, Venezia, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balance impairment is one of the most common disorders due to a neurological diseases.&#xD;
      Sensor-based technologies may be useful for falls prevention and balance recovery during&#xD;
      patients hospitalization. OAK Elderly Care System (Khymeia Group, Noventa Padovana, Italy)&#xD;
      allows the assessment of fall risk, the centre of pressure and the execution of balance&#xD;
      exercises in a virtual environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to compare the therapy provided by means of the OAK Elderly Care&#xD;
      System with conventional physiotherapy for balance rehabilitation in patients affected by&#xD;
      stroke, Multiple Sclerosis (MS) and Parkinson Disease (PD).&#xD;
&#xD;
      OAK Elderly Care System consists of two independent balance boards and three sensors for the&#xD;
      kinematic tracking of the trunk and lower limbs. These components allow the assessment of the&#xD;
      centre of pressure and the execution of exercises in a virtual environment.&#xD;
&#xD;
      120 patients (40 stroke, 40 MS, 40 PK) hospitalized at 4 different italian hospitals, were&#xD;
      enrolled according to inclusion and exclusion criteria and randomly assigned to two groups&#xD;
      (i.e. intervention group, control group). Intervention group received 1 daily hour of&#xD;
      technology-based treatment, while the control group underwent 1 daily hour of physiotherapy&#xD;
      for balance rehabilitation, in addiction to 1 hour of conventional physiotherapy. Both&#xD;
      treatments lasted 15 sessions. Before and after treatment balance, walking, daily living&#xD;
      autonomy and pathology-specific features were assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">March 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The experimental group is treated through a sensor-based devices in a virtual environment, while the control group is treated through conventional physiotherapy for balance rehabilitation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Berg Balance Scale (BBS)</measure>
    <time_frame>Change from baseline Berg Balance Scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means better outcome (minimum score = 0, maximum score = 56).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of falls during the last year</measure>
    <time_frame>Change from baseline number of falls during the last year scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ambulation Classification (FAC)</measure>
    <time_frame>Change from baseline Functional Ambulation Classification at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means better outcome (minimum score = 0, maximum score = 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities specific-Balance Confidence scale (ABC)</measure>
    <time_frame>Change from baseline Activities specific-Balance Confidence scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means better outcome (minimum score = 0, maximum score = 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Independence Measure (FIM)</measure>
    <time_frame>Change from baseline Functional Independence Measure at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means better outcome (minimum score = 0, maximum score = 126).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI)</measure>
    <time_frame>Change from baseline Barthel Index at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means better outcome (minimum score = 0, maximum score = 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institution of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Change from baseline National Institute of Health Stroke Scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means worse outcome (minimum score = 0, maximum score = 42).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>Change from baseline Unified Parkinson's Disease Rating Scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means worse outcome (minimum score = 0, maximum score = 147).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoehn &amp; Yahr Scale (H&amp;Y)</measure>
    <time_frame>Change from baseline Hoehn &amp; Yahr Scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means worse outcome (minimum score = 0, maximum score = 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kurtzke Extended Disability Status Scale (EDSS)</measure>
    <time_frame>Change from baseline Kurtzke Extended Disability Status Scale at the end of the therapy (three weeks thereafter)</time_frame>
    <description>Applied at the beginning and at the end of treatment (after 15 sessions). A higher score means worse outcome (minimum score = 0, maximum score = 10).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Instrumental assessment</measure>
    <time_frame>Change from baseline BBS at the end of the therapy (three weeks thereafter)</time_frame>
    <description>The OAK system will record the changes of the center of pressure during 30 seconds, with relaxed arms and eyes open.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stroke</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Experimental Group (EG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the EG the subjects will perform balance exercises using the OAK system under the supervision of a trained physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group (CG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the CG the subjects will be asked to perform conventional balance exercises under the supervision of a physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental Group</intervention_name>
    <description>The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.</description>
    <arm_group_label>Experimental Group (EG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.</description>
    <arm_group_label>Control Group (CG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Common criteria:&#xD;
&#xD;
          -  Berg Balance Scale &lt; 50/56;&#xD;
&#xD;
          -  Ability to maintain the standing position with o without one support for 1 minute;&#xD;
&#xD;
          -  Functional Independence measure &lt; 100/126;&#xD;
&#xD;
          -  Barthel Index &lt; 80/100.&#xD;
&#xD;
        Stroke:&#xD;
&#xD;
          -  Single ischemic stroke;&#xD;
&#xD;
          -  Lesion occured after 2 and within 18 months;&#xD;
&#xD;
          -  National Institute of Health Stroke Scale ≤ 14.&#xD;
&#xD;
        Parkinson:&#xD;
&#xD;
          -  1.5 &lt; Hoehn &amp; Yahr &lt; 3;&#xD;
&#xD;
          -  Subitem &quot;freezing when walking&quot;of the UPDRS ≤ 2.&#xD;
&#xD;
        Multiple Sclerosis:&#xD;
&#xD;
          -  Relapsing remitting or secondary progressive Multiple Sclerosis;&#xD;
&#xD;
          -  Expanded Disability Status Scale ≤ 6.5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated epilepsy;&#xD;
&#xD;
          -  Major depressive disorder;&#xD;
&#xD;
          -  Fractures;&#xD;
&#xD;
          -  Dementia;&#xD;
&#xD;
          -  Ideomotor Apraxia;&#xD;
&#xD;
          -  Neglect;&#xD;
&#xD;
          -  Severe impairment of verbal comprehension;&#xD;
&#xD;
          -  Severe acoustic and visual disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Turolla, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Camillo IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Turolla, PhD</last_name>
    <phone>00390412207</phone>
    <phone_ext>531</phone_ext>
    <email>andrea.turolla@ospedalesancamillo.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Fondazione Mondino</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Tassorelli, Prof.</last_name>
      <phone>0382380425</phone>
      <email>cristina.tassorelli@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Roberto De Icco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS ICS Maugeri Spa SB</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Maggioni, Dr.</last_name>
      <phone>0322884711</phone>
      <email>giorgio.maggioni@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana</name>
      <address>
        <city>Rom</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Franceschini, Dr.</last_name>
      <email>marco.franceschini@sanraffaele.it</email>
    </contact>
    <contact_backup>
      <phone>06660581</phone>
    </contact_backup>
    <investigator>
      <last_name>Michela Goffredo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Santa Lucia</name>
      <address>
        <city>Rom</city>
        <zip>00179</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Morone, Dr.</last_name>
      <email>g.morone@hsantalucia.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Camillo IRCCS</name>
      <address>
        <city>Venice</city>
        <zip>30126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesca Baldan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Federico</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martina Pavanetto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Camillo, Venezia, Italy</investigator_affiliation>
    <investigator_full_name>Andrea Turolla</investigator_full_name>
    <investigator_title>Laboratory Head</investigator_title>
  </responsible_party>
  <keyword>Balance</keyword>
  <keyword>Sensor-based rehabilitation</keyword>
  <keyword>Virtual Reality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

